Initial US Health Plan Disclosures On Drug Rebates And Patient Cost Sharing Postponed

Postponement of the transparency requirement established via late 2020 legislation may mean data from health plans may not be publicly available until 2024.

More clarity on rebates is still expected, just later. • Source: Alamy

The Biden Administration is postponing for one year the deadline of the first in an ongoing series of required annual reports from government-sponsored and commercial health plans to the federal government disclosing drug manufacturer rebates and their impact on health coverage premiums.

The initial reports, which will include 2020 and 2021 data, now are due 27 December 2022, instead of 27 December...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access